New drug cocktail tested for Tough-to-Treat brain cancers
NCT ID NCT05211336
Summary
This early-phase study is testing the safety of a combination of five drugs (called VIPOR) for people with aggressive B-cell lymphomas that involve the brain or spinal cord. The trial is for adults whose cancer has come back, stopped responding to treatment, or who cannot receive standard first-line therapy. The main goal is to see if patients can tolerate at least two treatment cycles without severe side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF THE CENTRAL NERVOUS SYSTEM (CNS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.